DaudiAiko
JF-Expert Member
- Dec 2, 2012
- 409
- 343
As sweet as the story goes, anything creative comes at a cost. Every tech company has to be guarded from the prying eyes of petty thieves.
Pharmaceutical companies that do research and development should always have the best interests of humanity at heart. This is why they should always be appreciated for the good deeds and their countless efforts to society.
Gilead pharmaceuticals should receive all their plaudits for a truly remarkable feat. Lenacapavir, the wonder drug with the potential to save millions of lives, especially in Sub-Saharan Africa. Just two shots per year, as opposed to the countless number of pills a HIV patient would need to take every year.Approved by the FDA, after a 99.9% success rate for PreP and post exposure prophylaxis. The closest we’ve ever gotten to a vaccine
Music to my ears. But what's the catch?. Whenever a pharmaceutical company discovers a drug, they get a 20 year patent, a period where they become the sole distributors of their invention. This is usually done to recoup the millions of dollars in research in an endeavor that often bares little fruit. After the patent expires, other pharmaceutical companies around the world are allowed to market the generics.
Indeed a single shot of Lenacapavir will cost a whooping 14,000 US dollars, leaving most Americans wondering whether or not it will be covered by Medicare.
HIV is a pandemic and the people most affected by the condition reside in Sub-Saharan Africa. As a result of the urgent situation, maybe the FDA could bend the rules to make cheaper options available to those who probably need it more than others
Pharmaceutical companies that do research and development should always have the best interests of humanity at heart. This is why they should always be appreciated for the good deeds and their countless efforts to society.
Gilead pharmaceuticals should receive all their plaudits for a truly remarkable feat. Lenacapavir, the wonder drug with the potential to save millions of lives, especially in Sub-Saharan Africa. Just two shots per year, as opposed to the countless number of pills a HIV patient would need to take every year.Approved by the FDA, after a 99.9% success rate for PreP and post exposure prophylaxis. The closest we’ve ever gotten to a vaccine
Music to my ears. But what's the catch?. Whenever a pharmaceutical company discovers a drug, they get a 20 year patent, a period where they become the sole distributors of their invention. This is usually done to recoup the millions of dollars in research in an endeavor that often bares little fruit. After the patent expires, other pharmaceutical companies around the world are allowed to market the generics.
Indeed a single shot of Lenacapavir will cost a whooping 14,000 US dollars, leaving most Americans wondering whether or not it will be covered by Medicare.
HIV is a pandemic and the people most affected by the condition reside in Sub-Saharan Africa. As a result of the urgent situation, maybe the FDA could bend the rules to make cheaper options available to those who probably need it more than others
